阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

休市中 07-26 16:00:00 EDT

78.13

-0.39

-0.50%

盘后78.25

+0.12+0.15%

19:59 EDT

最高79.45	最低78.08	成交量587.85万
今开78.48	昨收78.52	日振幅1.74%
总市值2,422亿	流通市值2,413亿	总股本31.01亿
成交额4.63亿	换手率0.19%	流通股本30.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":78.13,"timestamp":1722024000000,"preClose":78.52,"halted":0,"volume":5878523,"hourTrading":{"tag":"盘后","latestPrice":78.25,"preClose":78.13,"latestTime":"19:59 EDT","volume":50670,"amount":3959377.7587,"timestamp":1722038383850},"delay":0,"floatShares":3087986729,"shares":3100536150,"eps":2.024846,"marketStatus":"休市中","marketStatusCode":7,"change":-0.39,"latestTime":"07-26 16:00:00 EDT","open":78.48,"high":79.45,"low":78.08,"amount":462706011.05421,"amplitude":0.017448,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.024846,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1722240000000},"adr":1,"listingDate":737179200000,"adjPreClose":78.52,"adrRate":0.5,"dividendRate":0.012607,"preHourTrading":{"tag":"盘前","latestPrice":78.475,"preClose":78.52,"latestTime":"09:29 EDT","volume":519769,"amount":40694448.439615,"timestamp":1722000583166},"postHourTrading":{"tag":"盘后","latestPrice":78.25,"preClose":78.13,"latestTime":"19:59 EDT","volume":50670,"amount":3959377.7587,"timestamp":1722038383850},"volumeRatio":1.193216,"impliedVol":0.1979,"impliedVolPercentile":0.0437},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2454397856","title":"阿斯利康2024财年第二财季实现净利润19.27亿美元，同比增加6.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2454397856","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454397856?lang=zh_cn&edition=full","pubTime":"2024-07-26 16:18","pubTimestamp":1721981937,"startTime":"0","endTime":"0","summary":"7月26日，阿斯利康公布财报，公告显示公司2024财年第二财季净利润为19.27亿美元，同比增加6.00%；其中营业收入为129.38亿美元，同比增加13.33%，每股基本收益为0.62美元。从资产负债表来看，阿斯利康总负债647.42亿美元，其中短期债务53.59亿美元，资产负债比为0.01，流动比率为0.89。机构评级：截至2024年7月26日，当前有29家机构对阿斯利康目标价做出预测，其中目标均价为89.86美元，其中最低目标价为70.82美元，最高目标价为113.64美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407261619059eeca8d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407261619059eeca8d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZN"],"gpt_icon":0},{"id":"2454738875","title":"阿斯利康半年报增长 18%、一品红1类创新药获临床试验批准、核药领域获31亿融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2454738875","media":"医药经济报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454738875?lang=zh_cn&edition=full","pubTime":"2024-07-25 20:20","pubTimestamp":1721910002,"startTime":"0","endTime":"0","summary":"全球每年新增约130万艾滋病毒感染病例。阿斯利康财报发布今日，阿斯利康公布了其 2024 年上半年及第二季度的财报。总体而言，阿斯利康在上半年表现强劲，总收入达到 256.17 亿美元，同比增长 18%。一品红1类创新药获临床试验批准近日，一品红自主研发的1类创新药物APH01727片的药物临床试验申请已获得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，将于近期开展临床试验。目前，尚未在国内、外批准上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407252054049ee9fa36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407252054049ee9fa36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","BK4585","LU1829250122.USD","BK4568","BK4588","LU0109394709.USD","AZN","BK4007","LU2236285917.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2454682732","title":"阿斯利康(AZN)因强劲药品需求上调全年业绩预期 料今年收入和核心每股收益增长约15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2454682732","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454682732?lang=zh_cn&edition=full","pubTime":"2024-07-25 19:59","pubTimestamp":1721908771,"startTime":"0","endTime":"0","summary":"以固定汇率计算，阿斯利康最大的肿瘤学业务部门销售额同比增长了19%，达到了53.3亿美元，占公司总销售额的41%。尽管如此，阿斯利康仍对2024年的业绩持乐观态度，预计在固定汇率的基础上，公司的收入和核心每股收益将实现大约15%的增长。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"278202","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2236285917.USD","BK4568","BK4007","BK4585","LU1829250122.USD","BK4588","LU0320765992.SGD","AZN","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2454826293","title":"业绩超预期并上调指引，阿斯利康盘前股价却遭下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2454826293","media":"财华社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454826293?lang=zh_cn&edition=full","pubTime":"2024-07-25 19:08","pubTimestamp":1721905694,"startTime":"0","endTime":"0","summary":"7月25日盘前（当地时间），赛诺菲安万特（SNY.US）、罗氏（RHHBY.US）、阿斯利康（AZN.US）等一些医药巨头相继公布了最新的业绩情况。","market":"other","thumbnail":"https://images.finet.hk/photoLib/title/202407_1/af7f6e18-e302-48aa-b7cb-3749483f93e4.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202407_1/af7f6e18-e302-48aa-b7cb-3749483f93e4.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/66a2321ebde0b3054d3444af","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["LU2236285917.USD","BK4568","BK4007","BK4585","LU1829250122.USD","BK4588","LU0320765992.SGD","AZN","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"1112037800","title":"阿斯利康Q2营收超预期，受癌症和罕见疾病治疗需求的提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1112037800","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1112037800?lang=zh_cn&edition=full","pubTime":"2024-07-25 15:04","pubTimestamp":1721891099,"startTime":"0","endTime":"0","summary":"核心每股收益1.98美元。","market":"us","thumbnail":"https://static.tigerbbs.com/6e7ca4ce1f20e2902caaa13f0fa8bb2e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6e7ca4ce1f20e2902caaa13f0fa8bb2e"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"阿斯利康Q2营收超预期，受癌症和罕见疾病治疗需求的提振","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"gpt_icon":0},{"id":"2454814818","title":"阿斯利康(AZN.US)Q2营收同比增长13% 上调全年业绩指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2454814818","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454814818?lang=zh_cn&edition=full","pubTime":"2024-07-25 14:51","pubTimestamp":1721890312,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月25日，阿斯利康公布了2024年第二季度财务业绩。财报显示，阿斯利康Q2总营收为129.38亿美元，同比增长13%;其中，产品销售额为124.52亿美元，同比增长14%。具体来看，肿瘤学业务营收同比增长15%至53.31亿美元。心血管、肾脏和代谢业务营收同比增长18%至31.60亿美元。罕见病业务营收为21.47亿美元，同比增长10%。展望未来，由于强劲的产品销售和协作营收，阿斯利康上调了2024年全年营收和核心每股收益指引。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1155445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AZN"],"gpt_icon":0},{"id":"2454814523","title":"阿斯利康第二季度营收129.4亿美元，高于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2454814523","media":"观点网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454814523?lang=zh_cn&edition=full","pubTime":"2024-07-25 14:23","pubTimestamp":1721888580,"startTime":"0","endTime":"0","summary":"观点网讯：7月25日，阿斯利康公布了其2024年第二季度的财务报告。根据报告，公司营收达到129.4亿美元，超出市场预期的125.6亿美元。产品销售额为124.5亿美元，同样高于预估的119.3亿美元。此外，公司第二季度的核心每股收益为1.98美元，也超过了预期的1.95美元。阿斯利康在医药领域的业绩表现，以及在全球经济环境中的业绩增长，均体现在其财务报告中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407251445369ee8ccbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407251445369ee8ccbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZN"],"gpt_icon":0},{"id":"2453251045","title":"5.45亿美元！阿斯利康与Pinetree就EGFR降解剂达成独家选择权和全球许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2453251045","media":"凯莱英药闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453251045?lang=zh_cn&edition=full","pubTime":"2024-07-24 11:10","pubTimestamp":1721790656,"startTime":"0","endTime":"0","summary":"欢迎关注凯莱英药闻2024年7月23日，Pinetree Therapeutics宣布，已与阿斯利康就临床前表皮生长因子受体降解剂候选药物达成独家选择权和全球许可协议。根据协议条款，阿斯利康将拥有该EGFR降解剂的独家选择权，对其进行全球开发和商业化；Pinetree将获得高达 4500 万美元的预付款和近期付款，并有资格获得额外的开发和商业里程碑付款，总交易价值超过 5 亿美元，以及全球净销售额的分级特许权使用费。据不完全统计，目前在研的EGFR降解剂约20余种。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407241121269554e3d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407241121269554e3d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU0889565916.HKD","LU1829250122.USD","BK4585","BK4007","BK4588","AZN","BK4568","LU0320765992.SGD","LU2236285917.USD"],"gpt_icon":0},{"id":"2452127651","title":"百洋医药与阿斯利康中金合资10亿元在青岛设立创业投资基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2452127651","media":"观点网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452127651?lang=zh_cn&edition=full","pubTime":"2024-07-18 13:59","pubTimestamp":1721282340,"startTime":"0","endTime":"0","summary":"观点网讯：7月18日，百洋医药与阿斯利康中金在青岛共同投资成立了一家创业投资基金合伙企业（有限合伙），名为阿斯利康中金（青岛）创业投资基金。该基金的出资额为10亿元，主要经营范围包括私募基金从事股权投资、投资管理和资产管理等活动。企查查股权穿透显示，该公司由无锡阿斯利康中金创业投资合伙企业（有限合伙）、百洋医药(301015)等共同持股。此次合作是百洋医药在资本市场的一次布局，涉及股权投资等方式，以拓展其在医药领域的业务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407181419099f622b50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407181419099f622b50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","BK4585","LU1829250122.USD","BK4568","BK4588","LU0109394709.USD","AZN","BK4007","LU2236285917.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2450367535","title":"抗疫概念股普遍扬升 诺瓦瓦克斯医药(NVAX)涨逾4% 美国疾控中心建议年龄满6个月及以上人群接种疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2450367535","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450367535?lang=zh_cn&edition=full","pubTime":"2024-07-12 21:57","pubTimestamp":1720792643,"startTime":"0","endTime":"0","summary":"金吾财讯 | 抗疫概念股普遍扬升，诺瓦瓦克斯医药(NVAX)涨4.32%，Moderna(MRNA)涨3.41%，BioNTech(BNTX)涨2.20%，阿斯利康(AZN)涨1.92%，美疾病预防控制中心关于COVID-19的最新数据显示，截至6月底，44个州的感染人数正在增加或可能增加。美国疾病控制与预防中心建议年龄六个月及以上的人接种更新的COVID-19疫苗。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/MGY3NWNiZjgxNDI5NTMwNTcxNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGY3NWNiZjgxNDI5NTMwNTcxNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"277731","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NVAX","BK4585","159646","MRNA","BK4532","BK4547","BK4551","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4568","BK4548","BK4534","LU1829250122.USD","BK4533","LU2236285917.USD","BK4501","BK4535","BK4588","BK4139","BNTX","AZN"],"gpt_icon":0},{"id":"2449246786","title":"阿斯利康(AZN.US)Tagrisso小分子组合疗法再获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2449246786","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449246786?lang=zh_cn&edition=full","pubTime":"2024-07-06 07:45","pubTimestamp":1720223111,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，阿斯利康今日宣布，其表皮生长因子受体酪氨酸激酶抑制剂Tagrisso联合培美曲塞和铂类化疗已在欧盟获得批准，用于一线治疗肿瘤存在外显子19缺失或外显子21突变的晚期表皮生长因子受体突变非小细胞肺癌成年患者。Tagrisso是第三代、不可逆的EGFR-TKI，已在临床证实对NSCLC具有疗效。2024年2月，Tagrisso联合化疗获得美国FDA批准，用于局部晚期或转移性EGFRm NSCLC成人患者的一线治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765992.SGD","BK4007","LU0109394709.USD","AZN","LU2236285917.USD","BK4568","LU0889565916.HKD","LU1829250122.USD","BK4585","BK4588"],"gpt_icon":0},{"id":"2446516584","title":"德国支持民众接种由阿斯利康和赛诺菲针对呼吸道合胞病毒联合开发的疫苗，暂时还不支持接种辉瑞制药的疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2446516584","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446516584?lang=zh_cn&edition=full","pubTime":"2024-06-28 09:08","pubTimestamp":1719536891,"startTime":"0","endTime":"0","summary":"德国支持民众接种由 阿斯利康 和赛诺菲针对呼吸道合胞病毒联合开发的 疫苗 ，暂时还不支持接种 辉瑞制药 的疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062809171095e01ce0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062809171095e01ce0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999001176.SGD","SG9999002232.USD","BK4585","LU0289739699.SGD","SG9999003800.SGD","LU0889565916.HKD","LU0321505868.SGD","LU1023059063.AUD","LU0170899867.USD","LU0320765992.SGD","LU0234572021.USD","SG9999011175.SGD","LU0456855351.SGD","BK4581","AZN","PFE","BK4007","BK4550","LU1057294990.SGD","LU0321505439.SGD","LU1066051498.USD","LU0868494617.USD","LU1066053197.SGD","LU0122379950.USD","IE00BBT3K403.USD","IE0002270589.USD","BK4533","SGXZ57979304.SGD","LU0058720904.USD","BK4588","LU1829250122.USD","LU0109394709.USD","IE00B19Z3B42.SGD","LU2236285917.USD","SG9999013999.USD","BK4592","BK4534","IE00BLSP4452.SGD","IE00BLSP4239.USD","BK4568","SG9999002224.SGD","IE00B19Z3581.USD","SG9999001176.USD"],"gpt_icon":0},{"id":"2446852135","title":"阿斯利康投资（中国）有限公司申请II类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2446852135","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446852135?lang=zh_cn&edition=full","pubTime":"2024-06-27 16:56","pubTimestamp":1719478594,"startTime":"0","endTime":"0","summary":"金融界6月27日消息，据CDE官网沟通交流公示，于6月27日收到阿斯利康投资（中国）有限公司申请的“II类会议”，当前状态“处理中”。根据《药物研发与技术审评沟通交流管理办法》（2020年第48号通告），沟通交流会议分为Ⅰ类、Ⅱ类和Ⅲ类会议，就关键阶段重大问题进行沟通交流。Ⅱ类会议一般安排在申请后60日内召开，系指为药物在研发关键阶段而召开的会议，主要包括下列情形：新药临床试验申请前会议、药物Ⅱ期临床试验结束/Ⅲ期临床试验启动前会议、新药上市许可申请前会议、风险评估和控制会议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062717041095dda7ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062717041095dda7ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2236285917.USD","BK4588","LU0889565916.HKD","BK4007","BK4585","AZN","LU0109394709.USD","LU0320765992.SGD","LU1829250122.USD","BK4568"],"gpt_icon":0},{"id":"2446254833","title":"隔夜美股全复盘(6.27)| 美光盘后一度跌逾9%，三季报超预期，下季指引不够亮眼；联邦快递收涨近16%，年度利润指引超预期，FY25将回购25亿美元股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2446254833","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446254833?lang=zh_cn&edition=full","pubTime":"2024-06-27 08:25","pubTimestamp":1719447941,"startTime":"0","endTime":"0","summary":"美光盘后一度跌逾9%，三季报超预期，下季指引不够亮眼；联邦快递收涨近16%，年度利润指引超预期，FY25将回购25亿美元股票","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/815107","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU1551013425.SGD","GOOG","LU0106831901.USD","IE0004445015.USD","IE00BDCRKT87.USD","BK4507","LU0642271901.SGD","LU1861215975.USD","LU0348723411.USD","LU0256863811.USD","IE00BMPRXR70.SGD","IE00BJJMRX11.SGD","V","TSLA","LU0234572021.USD","LU0965509010.AUD","LU1935043536.SGD","AMZN","AZN","MA","IE00B19Z3581.USD","LU0690374961.EUR","LU0965509101.SGD","NVDA","IE0009356076.USD","IE00BKVL7J92.USD","FDX","F","BABA","KKR","IE0034235295.USD","LU0127658192.USD","LU1046421795.USD","NIO","LU0097036916.USD","RIVN","LU1914381329.SGD","BK4561","LU0130102774.USD","BK4581","META","AAPL","LU0170899867.USD","BK4567","BK4574","SSNLF","LU0320765992.SGD","LU0820562030.AUD","LU0823411888.USD","LU1429558221.USD","PDD","MSFT","JD","MU","LU0690374615.EUR","LU","LU0980610538.SGD","LU0149725797.USD"],"gpt_icon":0},{"id":"2446352362","title":"阿斯利康肺癌靶向药联合化疗新适应证获批，肺癌精准治疗还有哪些痛点","url":"https://stock-news.laohu8.com/highlight/detail?id=2446352362","media":"第一财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446352362?lang=zh_cn&edition=full","pubTime":"2024-06-26 17:17","pubTimestamp":1719393462,"startTime":"0","endTime":"0","summary":"6月26日，阿斯利康宣布，全球首个三代EGFR-TKI肺癌靶向药物奥希替尼联合化疗一线治疗EGFR突变晚期非小细胞肺癌的适应证在中国获批。奥希替尼联合化疗组患者的中位无疾病进展生存期比奥希替尼单药组延长了8.8个月。在中国，肺癌是恶性肿瘤发病和死亡的首位原因。肺癌治疗领域的进展，对癌症防治总体目标的实现具有重要意义。奥希替尼是EGFR突变阳性晚期NSCLC患者的一线治疗方案，通过奥希替尼联合化疗一线治疗可进一步让患者的生命得以延长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626171851af8f4ba0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626171851af8f4ba0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2236285917.USD","BK4588","LU0889565916.HKD","BK4007","BK4585","AZN","LU0109394709.USD","LU0320765992.SGD","LU1829250122.USD","BK4568"],"gpt_icon":0},{"id":"2446324543","title":"阿斯利康：肺癌靶向药物泰瑞沙?联合化疗一线治疗EGFR突变晚期非小细胞肺癌的适应症在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446324543","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446324543?lang=zh_cn&edition=full","pubTime":"2024-06-26 14:39","pubTimestamp":1719383945,"startTime":"0","endTime":"0","summary":"每经AI快讯，阿斯利康6月26日宣布，中国国家药品监督管理局于2024年6月18日正式批准泰瑞沙?（英文商品名：TAGRISSO?，通用名：甲磺酸奥希替尼片，以下简称“奥希替尼”）联合培美曲塞和铂类化疗药物用于具有表皮生长因子受体(EGFR)外显子19缺失或外显子21(L858R)置换突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202406263114408224.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202406263114408224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765992.SGD","BK4568","BK4007","LU0109394709.USD","BK4585","AZN","LU1829250122.USD","LU0889565916.HKD","LU2236285917.USD","BK4588"],"gpt_icon":0},{"id":"2446331226","title":"阿斯利康肺癌靶向药泰瑞沙新适应症在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446331226","media":"老虎证券","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446331226?lang=zh_cn&edition=full","pubTime":"2024-06-26 14:20","pubTimestamp":1719382828,"startTime":"0","endTime":"0","summary":"【阿斯利康肺癌靶向药泰瑞沙新适应症在中国获批】金十数据6月26日讯，阿斯利康(AZN.O)6月26日宣布，中国国家药品监督管理局于2024年6月18日正式批准泰瑞沙®联合培美曲塞和铂类化疗药物用于具有表皮生长因子受体(EGFR)外显子19缺失或外显子21(L858R)置换突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062614225395d92397&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062614225395d92397&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU1829250122.USD","BK4568","LU0320765992.SGD","BK4585","AZN","BK4007","LU0889565916.HKD","LU2236285917.USD","BK4588"],"gpt_icon":0},{"id":"2446381237","title":"阿斯利康(AZN.US)肺癌药物奥希替尼新适应症在华获批 联合化疗一线治疗EGFR突变晚期非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2446381237","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446381237?lang=zh_cn&edition=full","pubTime":"2024-06-26 10:57","pubTimestamp":1719370676,"startTime":"0","endTime":"0","summary":"据悉，该药本次获批的新适应症为联合化疗一线治疗EGFR突变晚期非小细胞肺癌。目前，奥希替尼已在美国、欧盟、中国和日本等100多个国家和地区获批作为单一疗法使用，批准的适应症包括局部晚期或转移性EGFRm非小细胞肺癌患者的一线治疗，局部晚期或转移性EGFR T790M突变阳性非小细胞肺癌患者的二线治疗，以及早期EGFRm非小细胞肺癌的辅助治疗。此外，该药还已在美国和其他一些国家获批联合化疗用于局部晚期或转移性EGFRm非小细胞肺癌患者的一线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AZN","BK4568","LU2236285917.USD","BK4585","BK4007","LU0320765992.SGD","BK4588","LU0109394709.USD","LU0889565916.HKD","LU1829250122.USD"],"gpt_icon":0},{"id":"2444103503","title":"阿斯利康(AZN.US)新药Truqap联合化疗乳腺癌后期试验未达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2444103503","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444103503?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:19","pubTimestamp":1718698756,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据最新研究显示，阿斯利康的新药Truqap并没有帮助患有一种难以治疗的乳腺癌患者延长寿命。阿斯利康潜在的抗癌新药Truqap最近在美国和欧盟获得批准，可用于治疗其他类型的乳腺癌。阿斯利康负责肿瘤研发的执行副总裁Susan Galbraith表示，这项新研究的结果令人失望，但可能有助于推进对某些途径的理解。Truqap目前分别在乳腺癌和前列腺癌的后期试验中进行测试。在伦敦早盘交易中，阿斯利康的股价几乎没有变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1136724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LU0109394709.USD","LU0889565916.HKD","BK4568","LU1829250122.USD","BK4588","BK4585","LU0320765992.SGD","AZN","LU2236285917.USD"],"gpt_icon":0},{"id":"2444103619","title":"阿斯利康(AZN.US)乳癌药联合化疗疗程后期临床未达生存期目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2444103619","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444103619?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:12","pubTimestamp":1718698320,"startTime":"0","endTime":"0","summary":"阿斯利康(AZN.US)  (AZN.L)周二(18日)宣布，其乳癌药Truqap联合化疗药品Paclitaxel疗程(CAPItello-290)，在后期临床测试阶段未能达至改善整体生存期的目标。阿斯利康表示，由于缺乏已知可操作生物标志目标，三阴性乳癌属最难医治的疾病之一；以化疗为基础的治疗方案仍是主流做法。阿斯利康英股早段靠稳，报12,428便士。(da/k)(美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20211209122201027_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20211209122201027_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1357297/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0889565916.HKD","BK4568","BK4585","LU0320765992.SGD","AZN","BK4588","LU2236285917.USD","LU1829250122.USD","LU0109394709.USD","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.012},{"period":"3month","weight":0.0394},{"period":"6month","weight":0.1644},{"period":"1year","weight":0.1466},{"period":"ytd","weight":0.1601}],"compareEarnings":[{"period":"1week","weight":-0.0083},{"period":"1month","weight":-0.002},{"period":"3month","weight":0.0712},{"period":"6month","weight":0.117},{"period":"1year","weight":0.2032},{"period":"ytd","weight":0.1454}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.483871,"avgChangeRate":-0.001106},{"month":2,"riseRate":0.387097,"avgChangeRate":-0.020166},{"month":3,"riseRate":0.580645,"avgChangeRate":0.030042},{"month":4,"riseRate":0.677419,"avgChangeRate":0.03301},{"month":5,"riseRate":0.516129,"avgChangeRate":0.008567},{"month":6,"riseRate":0.46875,"avgChangeRate":0.020173},{"month":7,"riseRate":0.59375,"avgChangeRate":-0.004436},{"month":8,"riseRate":0.451613,"avgChangeRate":-0.00136},{"month":9,"riseRate":0.580645,"avgChangeRate":0.00617},{"month":10,"riseRate":0.548387,"avgChangeRate":0.016698},{"month":11,"riseRate":0.516129,"avgChangeRate":0.001567},{"month":12,"riseRate":0.580645,"avgChangeRate":0.009222}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}